Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554981 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®
A Phase 4 study of Dry Eye Syndromes, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT02554981: Completed Phase 4 study of Dry Eye Syndromes, sponsored by Allergan.
NCT02554981 is a Phase 4 study of Dry Eye Syndromes that has completed, run by Allergan. The registered enrollment target is 51 participants, below the 411-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02554981, a Phase 4 study of Dry Eye Syndromes, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.
Primary Outcome
Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement).
Conditions Studied
Interventions
- DRUG Cyclosporine 0.05% Ophthalmic Emulsion
Study Locations (2)
Massachusetts
- Andover Eye Associates, Inc - Andover
Tennessee
- Total Eye Care, PA - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2016-03-24 |
| Phase | Phase 4 |
What the finished NCT02554981 record still lists
NCT02554981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 411-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Cyclosporine 0.05% Ophthalmic Emulsion is the first listed.
NCT02554981 reports a single indexed study location in Massachusetts, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02554981 about?
NCT02554981 is a clinical study titled "Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®". This study will evaluate the efficacy of Restasis® in participants with dry eye disease who engage in electronic visual tasking.
What is the current status of trial NCT02554981?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2015-07-21. Estimated completion is 2016-03-24.
What conditions does trial NCT02554981 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT02554981?
The interventions under investigation include: Cyclosporine 0.05% Ophthalmic Emulsion (DRUG).
Who is sponsoring clinical trial NCT02554981?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02554981 being conducted?
This trial has 2 study locations across Massachusetts, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02554981's enrollment target sits among peer trials
51 12th of 17 higher than 6 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ACCURATE Study for Subjects With Dry Eyes
COMPLETED · Phase 4
-
Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
COMPLETED · Phase 4
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
-
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
COMPLETED · NA
-
TrueTear in Sjogren's Disease Patients
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI